PhysIQ announced today that it entered into a strategic collaboration with InCarda Therapeutics.
Newark, California-based InCarda Therapeutics develops first-of-their-kind inhaled therapies for treating cardiovascular diseases.
IN CASE YOU MISSED IT
- Tidepool achieves new certification for open-source quality management system
- Glucotrack to bring implantable CBGM to automated insulin delivery system initiative in Europe
- Study says smart infusion pump interoperability can enhance medication delivery
- Satio, Nanowear collab to bring AI-powered biomarkers to drug delivery
- Aptar reports positive adherence results with iPump dose software
About Sean Whooley
Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.
